Risk factors for opportunistic infections in patients with inflammatory bowel disease M Toruner, EV Loftus Jr, WS Harmsen, AR Zinsmeister, R Orenstein, ... Gastroenterology 134 (4), 929-936, 2008 | 1241 | 2008 |
The Epidemiology of Community-AcquiredClostridium difficileInfection: A Population-Based Study S Khanna, DS Pardi, SL Aronson, PP Kammer, R Orenstein, JL St Sauver, ... Official journal of the American College of Gastroenterology| ACG 107 (1), 89-95, 2012 | 759 | 2012 |
Urinary tract infections in adults R Orenstein, ES Wong American family physician 59 (5), 1225-1234, 1999 | 368 | 1999 |
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study R Orenstein, E Dubberke, R Hardi, A Ray, K Mullane, DS Pardi, ... Clinical Infectious Diseases 62 (5), 596-602, 2016 | 195 | 2016 |
Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility CT Seto, P Jeraldo, R Orenstein, N Chia, JK DiBaise Microbiome 2, 1-11, 2014 | 179 | 2014 |
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial SMART Study Group* Annals of internal medicine 149 (5), 289-299, 2008 | 165 | 2008 |
Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. K Link, R Orenstein Southern medical journal 92 (7), 728-731, 1999 | 131 | 1999 |
Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors S Leekha, KC Aronhalt, LM Sloan, R Patel, R Orenstein American journal of infection control 41 (5), 390-393, 2013 | 130 | 2013 |
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection ER Dubberke, CH Lee, R Orenstein, S Khanna, G Hecht, DN Gerding Clinical Infectious Diseases 67 (8), 1198-1204, 2018 | 129 | 2018 |
An outbreak of Mycobacterium chelonae infections in tattoos LA Drage, PM Ecker, R Orenstein, PK Phillips, RS Edson Journal of the American Academy of Dermatology 62 (3), 501-506, 2010 | 118 | 2010 |
Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience NC Patel, CL Griesbach, JK DiBaise, R Orenstein Mayo Clinic Proceedings 88 (8), 799-805, 2013 | 112 | 2013 |
GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study Z Temesgen, M Assi, FNU Shweta, P Vergidis, SA Rizza, PR Bauer, ... Mayo Clinic Proceedings 95 (11), 2382-2394, 2020 | 106 | 2020 |
A targeted strategy to wipe out Clostridium difficile R Orenstein, KC Aronhalt, JE McManus, LA Fedraw Infection Control & Hospital Epidemiology 32 (11), 1137-1139, 2011 | 98 | 2011 |
Do protective devices prevent needlestick injuries among health care workers? R Orenstein, L Reynolds, M Karabaic, A Lamb, SM Markowitz, ES Wong American Journal of Infection Control 23 (6), 344-351, 1995 | 95 | 1995 |
Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole RM Prabhu, M Bonnell, BL Currier, R Orenstein Clinical Infectious Diseases 39 (7), e74-e77, 2004 | 89 | 2004 |
Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis JE Blair, YHH Chang, MR Cheng, LT Vaszar, HR Vikram, R Orenstein, ... Emerging infectious diseases 20 (6), 983, 2014 | 78 | 2014 |
Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009 TC Olson, T Bongartz, CS Crowson, GD Roberts, R Orenstein, ... BMC Infectious Diseases 11, 1-8, 2011 | 63 | 2011 |
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 … R Orenstein, ER Dubberke, S Khanna, CH Lee, D Yoho, S Johnson, ... BMC infectious diseases 22 (1), 245, 2022 | 62 | 2022 |
Failure of Caspofungin to Treat Brain Abscesses Secondary to Candida albicans Prosthetic Valve Endocarditis RM Prabhu, R Orenstein Clinical infectious diseases 39 (8), 1253-1254, 2004 | 59 | 2004 |
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Z Temesgen, CD Burger, J Baker, C Polk, CR Libertin, CF Kelley, ... The Lancet Respiratory Medicine 10 (3), 237-246, 2022 | 58 | 2022 |